1369TiP A dose exploration study of almonertinib for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with newly diagnosed or recurrent brain/leptomeningeal metastasis (ARTISTRY)

Approximately 25 to 40% of patients with NSCLC have brain metastases (BM) and 3% to 4% develop leptomeningeal metastases (LM). Prognosis for patients with NSCLC and BM or LM is dismal, which seriously affects the quality of life and survival of patients. Several therapeutic options have been applied to manage BM or LM. However, the efficacy is limited. More recently, EGFR-TKIs have shown potential as a treatment option for BM or LM NSCLC patients. Almonertinib (HS-10296), a third-generation EGFR tyrosine kinase inhibitor (TKI), efficiently penetrates the blood brain barrier.